RxDoctor Payments Data

Jordan Williams, NP

Family · Thomasville, GANPI 1376911677

Payments from drug & device makers

$2,451in general payments, 2019–2025

Across 132 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$670
  • Scilex Pharmaceuticals Inc.$313
  • Edwards Lifesciences$186
  • Nevro Corp.$176
  • AbbVie$152
  • Almatica Pharma LLC$134
  • plus $820 from 19 others

What the payments were for

  • Food & beverage$2,451100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,451 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$2,050
Medicare patients
20
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl138$131,945
Buprenorphine325$108,850
LinzessLinaclotide41$28,647
ZtlidoLidocaine32$17,547
ButransBuprenorphine22$8,407
Gabapentin516$7,742
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl28$6,693
Pregabalin363$6,300
Lubiprostone47$4,092
Tizanidine Hcl303$3,810
Tramadol Hcl236$3,716
Cyclobenzaprine Hcl173$2,307
Baclofen115$1,557
Buprenorphine Hcl73$1,422
Acetaminophen-CodeineAcetaminophen With Codeine51$1,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$670$131,945138 claims
AbbVieLinzess$152$28,64741 claims
Scilex Pharmaceuticals Inc.Ztlido$313$17,54732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →